Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

4.13USD
4:00pm EDT
Change (% chg)

$-0.01 (-0.24%)
Prev Close
$4.14
Open
$4.03
Day's High
$4.15
Day's Low
$4.02
Volume
10,547
Avg. Vol
18,065
52-wk High
$5.70
52-wk Low
$2.35

Latest Key Developments (Source: Significant Developments)

Cardiome names Justin Renz CFO
Tuesday, 16 May 2017 08:00am EDT 

May 16 (Reuters) - Cardiome Pharma Corp :Cardiome reports changes to senior management team.Says Justin Renz joins Cardiome as its new chief financial officer.Cardiome Pharma Corp says Jennifer Archibald, Cardiome's current CFO, has been appointed to position of chief business operations officer.  Full Article

Cardiome reports Q1 loss per share $0.20
Monday, 15 May 2017 04:00pm EDT 

May 15 (Reuters) - Cardiome Pharma Corp :Cardiome reports first quarter 2017 financial results.Q1 revenue $5.2 million versus $7.1 million.Q1 revenue view $7 million -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue about $28 million to $30 million.Q1 loss per share $0.20.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-0.53, revenue view $31.8 million -- Thomson Reuters I/B/E/S.Cardiome Pharma Corp says has amended its term loan agreement with crg-managed funds.Cardiome pharma corp says under terms of original term loan agreement, CRG provided $20.0 million to company.  Full Article

Cardiome announces amendment to term loan agreement with CRG-managed funds
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Cardiome Pharma Corp :Cardiome announces amendment to term loan agreement with CRG-managed funds.Cardiome Pharma Corp says amended agreement provides cardiome with up to $50 million of available borrowing capacity.Cardiome Pharma Corp says under terms of original term loan agreement, CRG provided $20 million to company.Cardiome Pharma Corp says under terms of amended agreement, crg will provide an additional $10 million to company on effective date of amended agreement.Cardiome Pharma - two additional tranches of $10 million each are available to company subject to certain conditions under terms of amended agreement.Cardiome Pharma Corp says loan matures on march 31, 2022.Cardiome Pharma Corp says amended agreement bears interest at 13% per annum.  Full Article

Cardiome's partner SteadyMed receives favorable ruling in its USPTO Inter Partes review
Monday, 3 Apr 2017 08:00am EDT 

Cardiome Pharma Corp : Cardiome's partner SteadyMed receives favorable ruling in its USPTO Inter Partes review . Cardiome Pharma Corp says in its ruling, PTAB found all 22 claims of '393 patent were unpatentable .Cardiome Pharma Corp says Cardiome currently expects to file for European Medicines Agency (EMA) approval of Trevyent during 2017.  Full Article

Cardiome receives Notice of Compliance from Health Canada for its BRINAVESS NDS
Tuesday, 14 Mar 2017 03:02pm EDT 

Cardiome Pharma Corp : Cardiome receives notice of compliance from Health Canada for its BRINAVESS NDS .Notice of compliance enables Cardiome to begin commercializing BRINAVESS in Canada.  Full Article

Cardiome Pharma Corp says Q4 loss per share $0.18
Tuesday, 7 Mar 2017 04:00pm EST 

Cardiome Pharma Corp : Reports FY 2016 revenue $25.3 million . Cardiome reports fourth quarter and full year 2016 financial results . Q4 revenue $7.0 million versus I/B/E/S view $6.3 million . Q4 loss per share $0.18 . Reports FY 2016 revenue up 21 percent . Q4 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S .Believe Xydalba sales in 2017, followed by Trevyent launch in 2018/19 will be start of strong revenue growth for years to come.  Full Article

Cardiome announces commercial launch of Xydalba(dalbavancin) in France
Friday, 3 Mar 2017 08:00am EST 

Cardiome Pharma Corp : Cardiome Pharma Corp - received authorization from French transparency pricing commission to begin selling Xydalba in France .Cardiome Pharma Corp - it has launched Xydalba in France after receiving authorization.  Full Article

Cardiome Pharma announces commercial launch of Xydalba in Germany
Tuesday, 20 Dec 2016 08:00am EST 

Cardiome Pharma Corp : Cardiome announces commercial launch of xydalba (dalbavancin) in Germany .Cardiome Pharma - expect to follow up commercialization of xydalba in UK, german markets with launches in European countries during first half of 2017.  Full Article

Cardiome Q2 loss per share $0.37
Tuesday, 9 Aug 2016 04:00pm EDT 

Cardiome Pharma Corp : Q2 revenue $5.9 million versus i/b/e/s view $6.8 million . Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S . Cardiome reports second quarter 2016 financial results . Q2 loss per share $0.37 .Cardiome pharma corp says gross margin decreased to 71.4% and 76.1% for three and six months ended june 30, 2016, respectively.  Full Article

Cardiome prices offering of 10 mln shares at $3.00 per share
Tuesday, 26 Jul 2016 08:38am EDT 

Cardiome Pharma Corp : Says aggregate gross proceeds to company of us$30 million . Cardiome announces pricing of public offering of 10,000,000 common shares .Offering of 10 million common shares from treasury at a price to public of $3.00 per common share.  Full Article

More From Around the Web

BRIEF-Cardiome names Justin Renz CFO

* Says Justin Renz joins Cardiome as its new chief financial officer